CompBrief BY VELARION

Companies BeOne Medicines Ltd.

BeOne Medicines (ONC): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me BeOne Medicines Ltd.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.
CEO total pay$17,943,521CEO John Oyler · source
Say-on-pay support94.86%Latest vote · source
CEO vs. named peers29th pct.Of 16 peer CEOs
CEO pay ratio218:1To the median employee · source

CEO pay, last three years

  • $18,925,730FY2023
  • $20,836,439FY2024
  • $17,943,521FY2025

CEO total pay was $17,943,521 in fiscal 2025, down from $20,836,439 in fiscal 2024.

FY2025: salary $1,133,000 · bonus $0 · stock awards $11,249,615 · option awards $3,749,967

Executives and directors

Aaron Rosenberg · CFOChan Lee · General CounselJohn Oyler · CEOLai Wang · PresidentXiaobin Wu · PresidentAlessandro Riva · Independent DirectorAnthony C. Hooper · Independent DirectorCharles L. Sawyers · Independent DirectorCorazon (Corsee) D. Sanders · Independent DirectorElizabeth F. Mooney · Independent DirectorFelix J. Baker · Independent DirectorMargaret Dugan · Independent DirectorMichael Goller · Independent DirectorOlivier Brandicourt · Independent DirectorQingqing Yi · Independent DirectorRanjeev Krishana · Independent DirectorShalini Sharp · Independent DirectorXiaodong Wang · Director

Frequently asked questions

Who was the highest-paid executive at BeOne Medicines Ltd. in fiscal 2025?
As disclosed, Lai Wang (President, Global Head of Research and Development) was the highest-paid executive at BeOne Medicines Ltd. in fiscal 2025, with total compensation of $18,319,310.
How does BeOne Medicines Ltd.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Oyler's total compensation ranked at the 29th percentile of BeOne Medicines Ltd.'s disclosed peer group.
What is BeOne Medicines Ltd.'s CEO-to-median employee pay ratio?
As disclosed, BeOne Medicines Ltd.'s CEO-to-median employee pay ratio was 218:1.
How did shareholders vote on BeOne Medicines Ltd.'s executive compensation?
As disclosed, 94.86% of shareholders supported BeOne Medicines Ltd.'s executive compensation in the latest say-on-pay vote.
How much does BeOne Medicines Ltd. spend in total on board compensation for fiscal 2025?
As disclosed, BeOne Medicines Ltd. reported total board compensation of $6,972,054 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Lai Wang$659,492$0$15,249,603$1,749,882$585,629$0$74,704$18,319,310
President, Global Head of Research and Development
John Oyler1,133,000011,249,6153,749,9671,676,8400133,82917,943,521
Co-Founder, Chairman and Chief Executive Officer
Xiaobin Wu862,41207,499,8312,499,932957,2770209,99912,029,451
President and Chief Operating Officer
Aaron Rosenberg660,00003,870,9571,290,337586,080021,0006,428,374
Chief Financial Officer
Chan Lee654,00002,849,678949,876580,752021,0005,055,306
Senior Vice President, General Counsel and Corporate Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Lai Wang$18,319,310$7,402,451$7,316,566↑ +10,916,859
John Oyler17,943,52120,836,43918,925,730↓ −2,892,918
Xiaobin Wu12,029,45111,138,09311,000,169↑ +891,358
Aaron Rosenberg6,428,3746,150,178—↑ +278,196
Chan Lee5,055,3064,676,1484,049,366↑ +379,158

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee oversees our compensation and benefit plans and policies, administers our equity incentive plans, reviews, and approves all compensation decisions relating to our executive officers, and makes recommendations to the Board of Directors on compensation for our Chief Executive Officer, Chief Financial Officer, President and Chief Operating Officer, and President, Global Head of Research and Development.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantPay Governance
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
John OylerPSU2025-06-10185,062370,123—740,246$7,499,831
Xiaobin WuPSU2025-06-10123,377246,753—493,5064,999,975
Aaron RosenbergOPTION2025-06-10——119,873—1,290,337
Lai WangRSU2025-12-31——427,895—9,999,906
Chan LeeOPTION2025-06-10——88,244—949,876
Aaron RosenbergPSU2025-06-1063,681127,361—254,7222,580,726
Lai WangOPTION2025-06-10——162,565—1,749,882
Aaron RosenbergRSU2025-06-10——63,674—1,290,231
Lai WangRSU2025-06-10——86,359—1,749,899
Xiaobin WuRSU2025-06-10——123,370—2,499,856
Lai WangPSU2025-06-1086,359172,718—345,4363,499,798
Xiaobin WuOPTION2025-06-10——232,245—2,499,932
Chan LeeRSU2025-06-10——46,878—949,893
John OylerOPTION2025-06-10——348,374—3,749,967
John OylerRSU2025-06-10——185,055—3,749,784

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
John Oyler$3,749,784$7,499,831$3,749,96750.0%
Xiaobin Wu2,499,8564,999,9752,499,93250.0%
Aaron Rosenberg1,290,2312,580,7261,290,33750.0%
Lai Wang11,749,8053,499,7981,749,88220.6%
Chan Lee949,8930949,8760.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Chan LeeOption27,84614.96—
Chan LeeRSU29,003—677,800
Chan LeeRSU29,874—698,155
WangRSU31,304—732,486
Chan LeePSU32,695—764,082
Chan LeeRSU32,799—766,513
Aaron RosenbergPSU39,533—923,886
Aaron RosenbergRSU40,573—948,191
Chan LeeRSU46,878—1,095,539
Xiaobin WuRSU46,969—1,097,666
WangRSU55,029—1,286,028
WangPSU56,329—1,316,409
Chan LeePSU62,504—1,460,718
Aaron RosenbergRSU63,674—1,488,061
WangRSU66,833—1,561,887
Chan LeeRSU73,567—1,719,261
Xiaobin WuRSU78,624—1,837,443
John OylerRSU83,512—1,951,675
Xiaobin WuPSU84,487—1,974,461
Aaron RosenbergPSU84,916—1,984,487
WangRSU86,359—2,018,210
Chan LeeOption88,24420.26—
WangOption88,64711.98—
Aaron RosenbergRSU88,920—2,078,060
Chan LeeOption93,58716.41—
Xiaobin WuRSU100,243—2,342,679
Chan LeeRSU105,599—2,467,849
WangPSU115,154—2,691,149
Chan LeeOption115,51812.23—
John OylerRSU117,936—2,756,164
Aaron RosenbergOption119,87320.26—
Xiaobin WuRSU123,370—2,883,157
WangRSU126,711—2,961,236
Aaron RosenbergRSU127,595—2,981,895
Xiaobin WuOption132,97711.98—
Aaron RosenbergOption142,74014.06—
WangOption162,56520.26—
John OylerPSU163,488—3,820,715
Xiaobin WuPSU164,502—3,844,412
John OylerRSU177,827—4,155,817
WangRSU181,857—4,249,998
John OylerRSU185,055—4,324,735
Xiaobin WuRSU190,060—4,441,702
WangOption190,42416.41—
WangOption198,91312.23—
Xiaobin WuOption232,24520.26—
John OylerOption236,01511.98—
John OylerPSU246,753—5,766,618
Xiaobin WuRSU272,805—6,375,453
Xiaobin WuOption285,40216.41—
Xiaobin WuOption298,37612.23—
John OylerOption348,37420.26—
John OylerRSU367,848—8,596,608
WangRSU427,895—9,999,906
John OylerOption506,29816.41—
John OylerRSU528,060—12,340,762
John OylerOption577,55112.23—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Xiaodong WangNot independent · Scientific Advisory (Co-Chair)$0$0$0$0$4,249,830$4,249,830
Anthony C. HooperIndependent · Audit · Nominating and Corporate Governance (Chair) · Commercial and Medical Affairs Advisory (Chair)128,341199,834199,95400528,129
Shalini SharpIndependent · Audit (Chair) · Nominating and Corporate Governance125,377199,834199,95400525,165
Margaret DuganIndependent · Compensation (Chair) · Scientific Advisory · Commercial and Medical Affairs Advisory115,000199,834199,95400514,788
Corazon (Corsee) D. SandersIndependent · Audit · Scientific Advisory · Commercial and Medical Affairs Advisory · Not standing for re-election102,500199,834199,95400502,288
Alessandro RivaIndependent · Nominating and Corporate Governance · Scientific Advisory (Co-Chair)95,000199,834199,95400494,788
Olivier BrandicourtIndependent · Audit · Commercial and Medical Affairs Advisory92,500199,834199,95400492,288
Ranjeev KrishanaIndependent · Compensation · Commercial and Medical Affairs Advisory · Not standing for re-election90,000199,834199,95400489,788
Qingqing YiIndependent · Compensation · Scientific Advisory · Not standing for re-election90,000199,834199,95400489,788
Michael GollerIndependent · Nominating and Corporate Governance · Scientific Advisory · Not standing for re-election85,000199,834199,95400484,788
Charles L. SawyersIndependent · Newly elected000000
Elizabeth F. MooneyIndependent · Audit · Compensation · Newly elected000000
John V. OylerEmployee director · Board Chair000—00
Felix J. BakerIndependent · Newly elected000000

Board fee structure and ownership guideline

Annual cash retainer$65,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)35,000 / 30,000 / 20,000
Stock ownership guidelineThe Compensation Committee has adopted share ownership guidelines applicable to our non-employee directors, the terms of which are described above under “Share Ownership Guidelines.”

Total cost of the board

ComponentFY2025
Cash retainers and fees$923,718
Equity awards (grant-date value)$1,798,506
All other compensation$4,249,830
Total cost of the board$6,972,054

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names BeOne Medicines as a peer

Companies that benchmark against ONC

7 companies name ONC as a compensation peer

Each company listed discloses ONC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ONC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

ALNY Alnylam Pharmaceuticals, Inc.NBIX Neurocrine Biosciences, Inc.REGN Regeneron Pharmaceuticals, Inc.BIIB Biogen Inc.UTHR United Therapeutics CorporationBMRN BioMarin Pharmaceutical, Inc.MRNA Moderna, Inc.VRTX Vertex Pharmaceuticals Inc.SRPT Sarepta Therapeutics, Inc.JAZZ Jazz Pharmaceuticals plcEXEL Exelixis, Inc.JAZZ Jazz Pharmaceuticals plcSRPT Sarepta Therapeutics, Inc.GILD Gilead Sciences, Inc.AMGN Amgen Inc.INCY Incyte Corporation

Peer reciprocity

The companies BeOne Medicines Ltd. names as compensation peers that name it back in their own disclosed peer groups.

Alnylam Pharmaceuticals, Inc. (ALNY)104Neurocrine Biosciences, Inc. (NBIX)105BioMarin Pharmaceutical, Inc. (BMRN)106Moderna, Inc. (MRNA)107Incyte Corporation (INCY)108

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2Incyte Corporation2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3Gilead Sciences, Inc.2025Daniel O'Day1,795,19215,238,4024,500,0604,848,12028,437,198
4Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
5Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
6BioMarin Pharmaceutical, Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
7Vertex Pharmaceuticals Inc.2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
8Moderna, Inc.2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
9Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
10United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
11BeOne Medicines Ltd.2025John Oyler1,133,00011,249,6153,749,9671,676,84017,943,521
12Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
13Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
14Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
15Regeneron Pharmaceuticals, Inc.2025Leonard Schleifer1,979,922——3,682,6557,280,549

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
BeOne Medicines Ltd.148%PSU 50 · Options 25 · RSU 25NoPay Governance
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
BioMarin Pharmaceutical, Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Gilead Sciences, Inc.180%PSU 50 · Option 25 · RSU 25Yes — Relative TSRFW Cook
Incyte Corporation138.6%PSU 60 · RSU 20 · Option 20Yes — relative total shareholder return (TSR)Aon
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Moderna, Inc.170%PSU 50 · Options 50NoPay Governance LLC
Neurocrine Biosciences, Inc.105%Option 50 · PRSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Regeneron Pharmaceuticals, Inc.155%Options 60 · RSU 40not disclosedPay Governance LLC
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
United Therapeutics Corporation221%PSO 50 · PSU 50NoAon
Vertex Pharmaceuticals Inc.not disclosedPSU 55 · RSU 45NoPearl Meyer

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-11975,327,10052,877,46032,815,94994.86%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-1194.86%a

a. Approved under the standard stated in the filing — “Advisory Vote on the Compensation of the Named Executive Officers ​ Vote Required and Board of Directors' Recommendation Approval of Proposal 10 requires the affirmative vote of a simple majority of the votes cast at the Annual Meeting. || Abstentions: Broker non-votes, blank ballots, invalid ballots and abstentions with respect to Proposal 10 will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the vote.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)218 : 1
CEO total compensation$17,943,521
Median employee compensation$82,226
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Xiaobin WuPresident and COO2026-08-25D280$380$106,400CommonForm 4 ↗
Titus B. BallPrincipal Accounting Officer2026-09-01D13235646,974CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D403,35100Derivative, Class A CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D6,2783512,205,174CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D6,5693502,300,951CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D10,6883493,733,141CommonForm 4 ↗
Xiaodong WangDirector2026-09-08A31,027371,144,896CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D1,721348598,930CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D1,517347526,993CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D2,841346983,433CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D1,181345407,897CommonForm 4 ↗
Xiaodong WangDirector2026-09-08D7,4923482,609,573CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-14D30,76800Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-14A30,768371,133,185CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-14A30,768371,133,185CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-14D30,76800Derivative, Class A CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D3,4993631,270,485CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D4,2393621,535,228CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D403,36400Derivative, Class A CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D738367271,012CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D14,5253675,324,550CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D3,4193641,244,747CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D2,241361809,120CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D4035914,366CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D12035943,045CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D16035757,115CommonForm 4 ↗
Xiaodong WangDirector2026-09-28A31,028371,144,933CommonForm 4 ↗
Xiaodong WangDirector2026-09-28D2,047366748,891CommonForm 4 ↗
Chan LeeSVP, General Counsel2026-09-30D1,115375418,125CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D6,5583532,312,148CommonForm 4 ↗
Xiaodong WangDirector2026-10-13A31,027371,144,896CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D1,260353445,078CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D403,35100Derivative, Class A CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D5,6813511,996,280CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D10,3613503,631,262CommonForm 4 ↗
Xiaodong WangDirector2026-10-13D7,1673502,505,306CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D403,36400Derivative, Class A CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D6,9033662,528,020CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D3,9653651,448,927CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D2,8413641,033,980CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D8,1483632,959,696CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D2,331362844,639CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D320361115,404CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D1,280360460,444CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D1,681359603,052CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D1,239358442,990CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D1,440356512,087CommonForm 4 ↗
Xiaodong WangDirector2026-10-27D880356312,892CommonForm 4 ↗
Xiaodong WangDirector2026-10-27A31,028371,144,933CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (108 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Lai Wang. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 18,319,310. View filing ↗
  • Section 01, John Oyler. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 127. As printed: 17,943,521. View filing ↗
  • Section 01, Xiaobin Wu. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 12,029,451. View filing ↗
  • Section 01, Aaron Rosenberg. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 6,428,374. View filing ↗
  • Section 01, Chan Lee. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 5,055,306. View filing ↗
  • Section 03, John Oyler PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Xiaobin Wu PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Aaron Rosenberg OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Chan Lee OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Aaron Rosenberg PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Lai Wang OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Aaron Rosenberg RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Xiaobin Wu RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Lai Wang PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Xiaobin Wu OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Chan Lee RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, John Oyler OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, John Oyler RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 218 : 1. View filing ↗
  • Section 08, Xiaodong Wang. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 4,249,830. View filing ↗
  • Section 08, Anthony C. Hooper. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 528,129. View filing ↗
  • Section 08, Shalini Sharp. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 525,165. View filing ↗
  • Section 08, Margaret Dugan. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 514,788. View filing ↗
  • Section 08, Corazon (Corsee) D. Sanders. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 502,288. View filing ↗
  • Section 08, Alessandro Riva. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 494,788. View filing ↗
  • Section 08, Olivier Brandicourt. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 492,288. View filing ↗
  • Section 08, Ranjeev Krishana. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
  • Section 08, Qingqing Yi. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
  • Section 08, Michael Goller. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 484,788. View filing ↗
  • Section 08, Charles L. Sawyers. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Elizabeth F. Mooney. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, John V. Oyler. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Felix J. Baker. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Xiaobin Wu 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Titus B. Ball 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chan Lee 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 94.86% (votes for as printed: 975,327,100). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 923,718 + equity 1,798,506 + all other 4,249,830 = 6,972,054, summed across the director compensation table rows.
  • Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
  • Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
  • Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
  • Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
  • Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
  • BioMarin Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical, Inc.'s own proxy. As printed: 21,927,563. View filing ↗
  • Vertex Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Inc.'s own proxy. As printed: 21,144,261. View filing ↗
  • Moderna, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. View filing ↗
  • Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
  • United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
  • BeOne Medicines Ltd. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. View filing ↗
  • Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
  • Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
  • Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
  • Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
  • Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Neurocrine Biosciences, Inc. reciprocity. DEF 14A. Neurocrine Biosciences, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, BioMarin Pharmaceutical, Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Moderna, Inc. reciprocity. DEF 14A. Moderna, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Incyte Corporation reciprocity. DEF 14A. Incyte Corporation names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Get the full report — $500